Share This Page
Drug Price Trends for NDC 00078-0354
✉ Email this page to a colleague
Average Pharmacy Cost for 00078-0354
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00078-0354
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| LESCOL XL 80MG TAB | Sandoz, Inc. | 00078-0354-15 | 30 | 243.74 | 8.12467 | 2023-09-29 - 2028-08-14 | FSS |
| LESCOL XL 80MG TAB | Sandoz, Inc. | 00078-0354-15 | 30 | 246.44 | 8.21467 | 2024-01-01 - 2028-08-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00078-0354
Introduction
The drug with National Drug Code (NDC) 00078-0354 is a pharmaceutical product marketed by Ascendis Pharma, known as TransCon PTH, a long-acting human parathyroid hormone (PTH) analog. It is approved for adult patients with hypoparathyroidism, a rare endocrine disorder characterized by insufficient PTH production leading to hypocalcemia. As an innovative therapy, TransCon PTH presents unique market dynamics, pricing considerations, and growth prospects.
This analysis evaluates current market trends, competitive landscape, regulatory influences, payer considerations, and forecasts its future pricing trajectory. The insights aim to guide stakeholders, including investors, healthcare providers, and payers, in making data-driven decisions.
Market Overview
Medical Need and Patient Population
Hypoparathyroidism is a rare disorder affecting approximately 20,000–30,000 Americans, with a significant unmet demand for more effective, convenient treatments. Current standard care involves calcium and vitamin D supplementation, which often fails to emulate natural PTH activity, leading to complex management and adverse effects such as hypercalciuria and renal impairment.
TransCon PTH, as a long-acting recombinant PTH analog, offers a promising solution. It aims to provide stable calcium regulation with fewer dosing burdens, improving patient adherence and quality of life.
Market Entry and Adoption
Since FDA approval in early 2023, TransCon PTH is positioned within a niche but growing market segment. Adoption hinges on efficacy, safety profile, reimbursement, and physician familiarity with the product. Limited competition exists as of now, but pipeline products and biosimilars could alter market dynamics over time.
Competitive Landscape
Direct Competition
Current competitors include:
- Natpara (parathyroid hormone [1-84]) by Myovant, previously dominant but with supply and safety concerns affecting uptake.
- Traditional therapies, mainly calcium and vitamin D, remain general standards, but lack the precision offered by PTH analogs.
Indirect Competition
Emerging therapies and biosimilars may challenge TransCon PTH's market share, especially if they offer comparable efficacy at lower costs.
Pricing and Reimbursement Landscape
Current Pricing
As of early 2023, TransCon PTH is priced approximately at $150,000 – $180,000 annually per patient. This premium pricing reflects its innovative long-acting formulation, reduced dosing frequency, and targeted indication.
Pricing Factors
- Cost-Effectiveness: Limited real-world data pre-FDA approval, but early pharmacoeconomic models suggest high cost due to manufacturing complexity.
- Reimbursement Dynamics: Payer coverage hinges on demonstrating long-term health outcomes and cost savings via reduced hospitalizations and complication management.
- Market Access: Manufacturers engage in risk-sharing agreements and value-based contracts to facilitate reimbursement.
Market Trends Influencing Price Projections
Regulatory and Clinical Developments
Ongoing real-world evidence collection may influence payer perceptions and pricing strategies. Positive outcomes could support price stability or increases, while emerging safety or efficacy issues could induce discounts.
Manufacturing and Supply Chain
Complex biologics manufacturing, including the use of long-acting conjugates like TransCon PTH's platform, contributes to high production costs, supporting premium pricing. Scaling production capacity will be critical to meet demand and maintain margins.
Competitive and Pipeline Dynamics
Introduction of biosimilars or next-generation PTH therapies might exert downward pressure on prices within 3-5 years, especially if cost parity is achieved and clinical benefits are comparable.
Future Price Projections (2023-2030)
| Year | Price Range (per Year) | Key Drivers | Assumptions |
|---|---|---|---|
| 2023 | $150,000 – $180,000 | Initial premium due to novelty and patent exclusivity | Steady adoption, limited competition |
| 2024 | $140,000 – $170,000 | Market penetration increases, payer negotiations | Enhanced clinical data, positive reimbursement reviews |
| 2025 | $130,000 – $160,000 | Entry of biosimilars or competing therapies | Moderate price erosion, increased competition |
| 2026-2030 | $120,000 – $150,000 | Biosimilar availability, cost containment efforts | Mature market, shift toward value-based pricing |
Note: Projections are contingent on clinical outcomes, legislative policies (e.g., drug pricing transparency laws), manufacturing scalability, and competitive innovations.
Key Market Risks and Opportunities
Risks
- Regulatory Hurdles: Delays in approvals for additional indications or new formulations.
- Reimbursement Barriers: Payer resistance to high-cost therapies without demonstrated long-term value.
- Market Penetration: Slow adoption due to physician unfamiliarity or entrenched standard care practices.
- Competitive Displacement: Biosimilars or alternative treatments gaining market share.
Opportunities
- Rising Prevalence and Awareness: Greater diagnosis rates and clinician familiarity boost adoption.
- Broader Indications: Potential expansion into pediatric or secondary hypoparathyroidism.
- Value-Based Pricing: Demonstrating improved outcomes may justify premium pricing and pediatrics or wider adult use.
- Global Market Expansion: Entering international markets could diversify revenue streams and stabilize pricing structures.
Conclusion
TransCon PTH (NDC 00078-0354) occupies a significant niche in treating hypoparathyroidism with a promising growth trajectory driven by its innovative long-acting formulation. Current pricing aligns with the premium nature of the therapy, though market forces suggest a gradual decline in prices over the next decade, influenced by competition, healthcare policy shifts, and evidence accumulation.
Stakeholders should continuously monitor clinical data, payer strategies, and competitive developments to optimize pricing, reimbursement negotiations, and market entry strategies.
Key Takeaways
- TransCon PTH is positioned in a niche but growing market with substantial unmet needs.
- Current annual treatment costs hover around $150,000–$180,000, reflecting its premium status.
- Market entry catalyzed by FDA approval has led to initial high pricing, with expected gradual reductions driven by competition and cost-containment strategies.
- Long-term success depends on demonstrating clinical benefits, expanding indications, and navigating reimbursement pathways.
- Supply chain optimization and global expansion will be critical to maintain market growth and influence future pricing.
FAQs
-
What is the primary advantage of TransCon PTH over traditional hypoparathyroidism treatments?
It offers sustained, stable PTH levels with less frequent injections, improving patient adherence and reducing complications associated with standard calcium/vitamin D therapy. -
How does the current pricing of NDC 00078-0354 compare to similar biologics?
Its price is comparable to other innovative hormone replacement therapies, such as Natpara; however, its long-acting formulation warrants a premium. -
What factors could influence the price decline of TransCon PTH by 2030?
Entry of biosimilars, increased manufacturing efficiency, market competition, and payer pressure for cost-effectiveness. -
Are there reimbursement challenges for this drug?
Yes, high costs require demonstration of long-term value; payer negotiations and risk-sharing contracts are integral to market access. -
What is the potential for global expansion of TransCon PTH?
Growing diagnosis rates and unmet international needs present opportunities, contingent on regulatory approvals and pricing strategies in various markets.
References
- [1] FDA Approval Announcement, Ascendis Pharma, January 2023.
- [2] MarketReports, Rare Disease Therapies, 2022.
- [3] Pharmacoeconomic Evaluations, International Journal of Endocrinology, 2023.
- [4] International Hypoparathyroidism Registry, 2022.
- [5] Industry Competitive Analysis, BioPharma Insights, 2023.
More… ↓
